Pfizer (PFE) Secures Patent Exclusivity for Vyndamax Through 2031 via Generic Settlement
Patent Dispute Settlement and Exclusivity Extension
Pfizer (PFE) has entered into a patent‑infringement settlement with three generic manufacturers—Dexcel Pharma, Hikma Pharmaceuticals, and Cipla—to delay the launch of a generic version of Vyndamax (tafamidis), its treatment for transthyretin amyloid cardiomyopathy (ATTR‑CM). Under the agreement, the U.S. patent exclusivity for Vyndamax, originally set to expire in 2028, is extended to June 1 20231. This gives Pfizer a multi‑year runway to protect a major cash‑cow product and avoid the financial shock of a looming patent cliff.
Vyndamax’s Dominant Market Position
Vyndamax is a TTR stabilizer that binds unstable transthyretin (TTR) protein, preventing amyloid deposition. Priced at approximately $250,000 per patient per year, it is a ultra‑high‑price orphan drug. In the last fiscal year, global sales topped $6.4 billion, establishing Vyndamax as a core blockbuster in Pfizer’s portfolio. Although generic manufacturers filed patent‑invalidity lawsuits beginning in 2023, Pfizer’s settlement strategy has postponed the entry of low‑cost copies by more than three years.
Mixed Impact on Competing Innovators
The extended exclusivity creates a significant strategic variable for competitors such as BridgeBio Pharma (BBIO) and Alnylam Pharmaceuticals (ALNY). BridgeBio’s ATTR‑CM TTR stabilizer, Attruby (acoramidis), received FDA approval on November 22 2024 and is now entering the market. Alnylam’s TTR‑targeted RNAi therapy, Amvuttra (vutrisiran), secured an ATTR‑CM indication on March 20 2025. With generic entry pushed to 2031, both innovators can maintain the original price tier of the reference product while expanding market share in a relatively protected environment.
AstraZeneca and Ionis: Potential Beneficiaries
AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) are co‑developing an antisense oligonucleotide (ASO) that targets TTR mRNA—Eplontersen (brand name Wainua). The therapy is currently in a large‑scale Phase 3 CARDIO‑TTRansform trial enrolling over 1,400 patients, with recruitment complete. The continued patent barrier around Vyndamax is expected to act as a shield for Eplontersen, preventing aggressive price‑cutting competition at launch and supporting a premium pricing strategy.
Patient Access Concerns and Ongoing Legal Risk
Delaying generic entry through settlement agreements is frequently labeled a “pay‑for‑delay” arrangement and draws intense antitrust scrutiny from regulators such as the U.S. Federal Trade Commission (FTC). The near‑$250,000 annual price continues to generate criticism from patient advocacy groups and healthcare providers, who argue that it hampers long‑term patient access. Moreover, Pfizer remains involved in additional patent litigations with generic firms like Apotex, meaning the durability of the exclusivity through 2031 could still be affected by pending court outcomes.
By extending exclusivity for Vyndamax—Pfizer’s $6.4 billion annual revenue asset—through 2031, the company has secured short‑term protection of a high‑margin cash flow equivalent to roughly $250,000 per patient per year. In the medium to long term, the settlement creates a favorable competitive landscape for other TTR‑targeted therapies, such as BridgeBio’s Attruby (approved November 2024) and Alnylam’s Amvuttra (approved March 2025), allowing them to compete without early generic pressure and to operate under Pfizer’s premium price benchmark. AstraZeneca and Ionis’s Eplontersen is also positioned to benefit from a smoother price‑defense pathway once Phase 3 CARDIO‑TTRansform is completed. However, the arrangement may attract FTC antitrust investigations into potential pay‑for‑delay practices, and unresolved patent disputes with firms like Apotex represent a lingering risk to Pfizer’s mid‑ to long‑term outlook.